Mounting evidence of the benefits of bone anabolic agents, such as anti-DKK-1, anti-RANKL, antisclerostin, and anti-TGF-β, will herald improvements in the treatment of MBD. This evidence concerns the gene TNFSF11 and Marchiafava-Bignami disease.